Image by Getty Images via Daylife
Sheng Ding, the leader of a group of researchers at the Scripps Research Institute of the La Jolla University in California, spoke about using chemistry-related techniques to obtain pluripotent stem cells from a miniscule section of skin at Milan University in a conference on stem cells.
Experts were able to cause some skin cells in mice to regress to their embryonic state by injecting four proteins into an adult mouse without performing any sort of DNA manipulation. A technique that, according to their idea, could be safer than techniques based on genetic manipulation. The
Researchers found stem cells in the ovaries of young women that have the potential to become healthy eggs. Applications of this discovery may help women have children that were once too old to or left infertile because of disease.
Natalie Melgar-Fetzer, a junior in ICS from Maryland said “It’s interesting because it can give women with reproductive problems the opportunity to have children. So many people want to have babies but can’t for whatever reason.”
Researchers have already created potentially viable eggs from these stem cells by adding a protein to them as well as a gene that makes jellyfish glow
The use of stem cells has often been a controversial issue in the media. International Stem Cell Corp. looks set to tackle the issue head on after launching its own line of stem cell based beauty products. According to reports online the skin care range was created by its wholly owned subsidiary Lifeline Skin Care.
CEO of Lifeline Skin Care, Dr. Ruslan Semechkin, was quoted as saying, “The commercial launch of the new skin care products represents an important step in the execution of ISCO`s strategy.” Plastic surgeon Dr. Gregory S. Keller described the new range as “…a huge step
International Stem Cell Corporation, a California-based biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent for a method of creating pure populations of definitive endoderm, precursor cells to liver and pancreas cells, from human pluripotent stem cells. This patent is a key element of ISCO’s metabolic liver disease program and allows the Company to produce the necessary quantities of precursor cells in a more efficient and cost effective manner.
The patent, 8,268,621, adds to the Company’s growing portfolio of proprietary technologies relating to the development of potential treatments
UC Davis Health System researchers who are working to speed therapies to patients suffering from critical limb ischemia, osteoporosis and Huntington’s disease received approval today for three separate research grants from the state’s stem cell agency totaling more than $53 million. Each of the research studies that can now begin at UC Davis are specifically designed to lead to U.S. Food and Drug Administration approval of human clinical trials using stem cells and regenerative therapies.
At today’s meeting of the California Institute for Regenerative Medicine (CIRM) in San Francisco, the agency’s 29-member governing board approved five other grant